#15 Atenolol & Beta-Blockers for Primary Hypertension: Do They Perform Under Pressure?
CLINICAL QUESTION
Are beta-blockers, particularly atenolol, as effective as other antihypertensive medications in preventing important outcomes in hypertensive patients?
BOTTOM LINE
Atenolol is an inferior choice for blood pressure treatment. Other antihypertensive classes (ACEI/ARB, calcium-channel blocker, diuretic) should all generally be considered first before using beta-blockers in patients with uncomplicated hypertension.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Multiple large meta-analyses have examined this question:
- 2005 meta-analysis1 compared all beta-blockers against other antihypertensives (13 trials; 105,951 patients) over 2.7-10 years.
- Beta-blockers versus all other antihypertensives:
- Statistically significantly increased risk of stroke [Number Needed to Harm (NNH)=461].
- No difference in myocardial infarction or death.
- Atenolol versus non-beta-blocker antihypertensives:
- Statistically significant increased stroke (NNH ~130) and death (NNH ~140).
- Beta-blockers versus all other antihypertensives:
- Similar results in 2004 meta-analysis by same authors,2 Cochrane review,3 and newer meta-analysis.4
- Beta-blockers worse than ACEIs/ARBs, calcium-channel blockers, and diuretics.4
- 2006 meta-analysis5 stratifying trials by age subgroup found different effects when comparing beta-blockers to other antihypertensives:
- <60 years: Relative risk 0.97 (0.88-1.07).
- >60 years: Relative risk 1.06 (1.01-1.10).
- Limitations: Age cutoff arbitrary and based on trial-wide mean age rather than individual-patient data, thus between-age difference could merely be due to chance or methodological differences between trials.
- 2014 meta-analysis found largely consistent results between atenolol and other beta-blockers versus other antihypertensives.6
- Guidelines recommend against beta-blockers as 1st-line therapy for uncomplicated hypertension in general (UK7) or specifically in patients >60 years (Canada8), unless there are comorbid conditions which benefit from beta-blockers.
- Beta-blockers are highly effective agents in patients with other indications (such as post-myocardial infarction9 or heart failure with reduced ejection fraction10).
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
